Microbot Medical Stock Performance
| MBOT Stock | USD 2.28 0.05 2.24% |
On a scale of 0 to 100, Microbot Medical holds a performance score of 6. The company secures a Beta (Market Risk) of 1.71, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Microbot Medical will likely underperform. Please check Microbot Medical's value at risk, and the relationship between the jensen alpha and skewness , to make a quick decision on whether Microbot Medical's current price movements will revert.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Microbot Medical are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady basic indicators, Microbot Medical unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 2.24 | Five Day Return 34.12 | Year To Date Return 100 | Ten Year Return (99.85) | All Time Return (100.00) |
Last Split Factor 1:15 | Dividend Date 2018-09-05 | Last Split Date 2018-09-05 |
1 | Acquisition by Stockburger Aileen Ptucha of 6493 shares of Microbot Medical at 6.16 subject to Rule 16b-3 | 01/22/2025 |
2 | Microbot Medical regains Nasdaq compliance with bid price - Investing.com | 01/27/2025 |
3 | Acquisition by Laxminarain Prattipati of 10000 shares of Microbot Medical at 1.93 subject to Rule 16b-3 | 01/28/2025 |
4 | Microbot Medical Announces 13 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules | 02/10/2025 |
5 | Microbot Medical Closes 13 Million Registered Direct Offering | 02/11/2025 |
6 | Robotic Telesurgery Data from Collaboration with Corewell Health Accepted for Presentation at the Cardiovascular Research Technologies Annual Meeting | 02/25/2025 |
7 | Microbot Medical Appoints Seasoned Endovascular Sales Executive | 03/04/2025 |
8 | Microbot Medical files to sell 12.54M shares of common stock for holders | 03/10/2025 |
9 | REMINDER Microbot Medical Announces Data from the Companys ACCESS-PVI trial will be Presented via Podium Presentation at Society of Interventional Radiology Ann... | 04/01/2025 |
10 | Microbot Medical Unveils Promising Trial Data for LIBERTY System | 04/09/2025 |
11 | Microbot Medicals Robotic System Achieves Key Trial Success | 04/11/2025 |
| Begin Period Cash Flow | 2.5 M |
Microbot |
Microbot Medical Relative Risk vs. Return Landscape
If you would invest 179.00 in Microbot Medical on January 15, 2025 and sell it today you would earn a total of 49.00 from holding Microbot Medical or generate 27.37% return on investment over 90 days. Microbot Medical is currently generating 0.6307% in daily expected returns and assumes 7.2379% risk (volatility on return distribution) over the 90 days horizon. In different words, 64% of stocks are less volatile than Microbot, and 88% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Microbot Medical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Microbot Medical's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Microbot Medical, and traders can use it to determine the average amount a Microbot Medical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0871
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | MBOT | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.24 actual daily | 64 64% of assets are less volatile |
Expected Return
| 0.63 actual daily | 12 88% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 6 94% of assets perform better |
Based on monthly moving average Microbot Medical is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Microbot Medical by adding it to a well-diversified portfolio.
Microbot Medical Fundamentals Growth
Microbot Stock prices reflect investors' perceptions of the future prospects and financial health of Microbot Medical, and Microbot Medical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Microbot Stock performance.
| Return On Equity | -2.85 | ||||
| Return On Asset | -1.01 | ||||
| Current Valuation | 73.86 M | ||||
| Shares Outstanding | 34.74 M | ||||
| Price To Earning | (3.42) X | ||||
| Price To Book | 22.44 X | ||||
| EBITDA | (11.53 M) | ||||
| Net Income | (11.44 M) | ||||
| Cash And Equivalents | 9.29 M | ||||
| Cash Per Share | 1.31 X | ||||
| Total Debt | 111 K | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 5.60 X | ||||
| Book Value Per Share | 0.18 X | ||||
| Cash Flow From Operations | (8.83 M) | ||||
| Earnings Per Share | (0.73) X | ||||
| Market Capitalization | 79.22 M | ||||
| Total Asset | 6.03 M | ||||
| Retained Earnings | (90.94 M) | ||||
| Working Capital | 3.36 M | ||||
| Current Asset | 15.21 M | ||||
| Current Liabilities | 9.83 M | ||||
About Microbot Medical Performance
Assessing Microbot Medical's fundamental ratios provides investors with valuable insights into Microbot Medical's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Microbot Medical is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (130.16) | (136.67) | |
| Return On Tangible Assets | 0.03 | 0.03 | |
| Return On Capital Employed | (2.50) | (2.37) | |
| Return On Assets | 0.03 | 0.03 | |
| Return On Equity | 0.05 | 0.05 |
Things to note about Microbot Medical performance evaluation
Checking the ongoing alerts about Microbot Medical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Microbot Medical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Microbot Medical is way too risky over 90 days horizon | |
| Microbot Medical appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (11.44 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Microbot Medical currently holds about 9.29 M in cash with (8.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.31. | |
| Microbot Medical has a poor financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Microbot Medicals Robotic System Achieves Key Trial Success |
- Analyzing Microbot Medical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Microbot Medical's stock is overvalued or undervalued compared to its peers.
- Examining Microbot Medical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Microbot Medical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Microbot Medical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Microbot Medical's stock. These opinions can provide insight into Microbot Medical's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Microbot Stock Analysis
When running Microbot Medical's price analysis, check to measure Microbot Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Microbot Medical is operating at the current time. Most of Microbot Medical's value examination focuses on studying past and present price action to predict the probability of Microbot Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Microbot Medical's price. Additionally, you may evaluate how the addition of Microbot Medical to your portfolios can decrease your overall portfolio volatility.